Brought to you by 
Eli Lilly, Ono develop and market respiratory pharmaceutical
18 Jun 2003
Executive Summary
Eli Lilly signed a letter of intent for an exclusive worldwide license--except in Japan, South Korea, and Taiwan--to Ono Pharmaceutical's (prostaglandins and enzyme inhibitors) Phase II sivelestat for acute lung injury and acute respiratory distress syndrome requiring mechanical ventilation.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com